Oral Opportunity in PsO (US) 2024, highlights a shifting landscape in the treatment for moderate-to-severe PsO. As emerging oral therapies gain traction, the study underscores their potential to ...

In the phase 4 FOREMOST trial, treatment with apremilast improved both clinical and patient-reported outcomes at week 16 among patients with early oligoarticular PsA.

The following is a summary of “Interstitial Lung Disease in Patients With Rheumatoid Arthritis or Psoriatic Arthritis ...

Wall St. Insights The 2025 Social Security COLA will be only 2.5%. The COLA increase will equal about $50 per person each ...

The Food and Drug Administration (FDA) has approved Imuldosa ™ (ustekinumab-srlf), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Imuldosa, ...

At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...

Imuldosa is used for the treatment of patients with autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

UCB SA (OTCMKTS:UCBJF – Get Free Report) was the recipient of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 419,400 ...

Individuals with self-reported moderate to severe psoriatic arthritis (PsA) face a higher disease burden, particularly among ...

Fatigue is a common problem for people with psoriatic arthritis. According to the National Psoriasis Foundation, some studies indicate that half of all psoriatic arthritis patients have ...

MoonLake Immunotherapeutics' stock has been volatile but is currently back to its previous year's level. Click here for more ...